Download full report with analyst certification and important disclosures
Sep 1 2021, 07:15 IST/BST
Uniphar
H1 21 results: growth platforms continue to deliver
- Sectors : Pharma and healthcare
- Companies : Uniphar
DAVY VIEW
Uniphar continues to make excellent progress. The two growth platforms, Commercial & Clinical and Product Access, delivered 24% and 15% organic gross profit growth respectively in H1 21. Management has also, unsurprisingly, reinvested some of this ‘outperformance’ back in the business to support future growth. The net result is an impressive +36% growth in EBITDA and +39% growth in adjusted EPS. ROCE also continues to trend above the group’s mid-term target at 17.6%. Conference call is at 09.00.
